GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » ROC (Joel Greenblatt) %

Genprex (Genprex) ROC (Joel Greenblatt) % : -252,084.21% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Genprex ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Genprex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -252,084.21%.

The historical rank and industry rank for Genprex's ROC (Joel Greenblatt) % or its related term are showing as below:

GNPX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -204473.68   Med: -66197.22   Max: -4008.63
Current: -204473.68

During the past 9 years, Genprex's highest ROC (Joel Greenblatt) % was -4008.63%. The lowest was -204473.68%. And the median was -66197.22%.

GNPX's ROC (Joel Greenblatt) % is ranked worse than
99.12% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs GNPX: -204473.68

Genprex's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -54.20% per year.


Genprex ROC (Joel Greenblatt) % Historical Data

The historical data trend for Genprex's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex ROC (Joel Greenblatt) % Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -4,008.63 -6,555.47 -46,977.27 -66,197.22 -200,490.32

Genprex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101,215.38 -176,590.48 -189,082.35 -239,569.23 -252,084.21

Competitive Comparison of Genprex's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Genprex's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Genprex's ROC (Joel Greenblatt) % falls into.



Genprex ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.146) - (1.179 + 0 + 3.159)
=-3.192

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.794) - (1.398 + 0 + 1.856)
=-2.46

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Genprex for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-23.948/( ( (0.011 + max(-3.192, 0)) + (0.008 + max(-2.46, 0)) )/ 2 )
=-23.948/( ( 0.011 + 0.008 )/ 2 )
=-23.948/0.0095
=-252,084.21 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex  (NAS:GNPX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Genprex ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Genprex's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex (Genprex) Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.
Executives
Catherine M Vaczy officer: EVP & Chief Strategy Officer C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner director, 10 percent owner, officer: Chief Executive Officer P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar officer: Chief Mfgr & Tech Officer 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker director C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio director 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr. director 1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman officer: EVP & Chief Operating Officer 16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc. director, 10 percent owner, officer: Chief Executive Officer 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham officer: Chief Operating Officer 944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth 10 percent owner 6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance 10 percent owner 8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer officer: Chief Financial Officer 1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson director 3001 MEANDERING RIVER COURT, AUSTIN TX 78746

Genprex (Genprex) Headlines

From GuruFocus